Related references
Note: Only part of the references are listed.High-Dose Treatment With Telmisartan Induces Monocytic Peroxisome Proliferator-Activated Receptor-γ Target Genes in Patients With the Metabolic Syndrome
Ilse-Nirmala Baehr et al.
HYPERTENSION (2011)
Characterization of New PPARγ Agonists: Analysis of Telmisartan's Structural Components
Matthias Goebel et al.
CHEMMEDCHEM (2009)
Inhibiting angiotensin type 1 receptors as a target for diabetes
Ulrich Kintscher et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2008)
Telmisartan, ramipril, or both in patients at high risk for vascular events
Salim Yusuf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Molecular characterization of new selective peroxisome proliferator-activated receptor γ modulators with angiotensin receptor blocking activity
M Schupp et al.
DIABETES (2005)
Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-α activity
M Schupp et al.
CIRCULATION (2004)
Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity
SC Benson et al.
HYPERTENSION (2004)
Share Paper
